| Project/Area Number |
23791485
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 乳腺外科学 / breast cancer / HER2 / 乳がん / TS |
|---|
| Research Abstract |
Fluoropyrimidine (5-FU) is key drug in treatment of breast cancer. Overexpression of thymidylate synthase (TS) confers resistant to 5-FU. The researchers have reported that TS expression is regulated by PI3K/Akt/mTOR pathway and have investigated TS targeting therapy to enhance antitumor effect of 5-FU therapy. In vitro, trastuzumab and lapatinib inhibited TS expression and transcription, and enhanced anti-tumor effect of 5-FU in SkBr3. However, in de-novo and acquired trastuzumab-resistant breast cancer cell lines showed no suppression of TS by HER2-targeting therapy, which was conferred by upregulation of PI3K/Akt/mTOR signaling and ofHER2-internalization. The researchers concluded that TS-inhibition therapy is effective in trastuzumab-sensitive HER2 positive breast cancer. Besides above findings, we found HER2-containing dimer as a novel predictive factor of HER2-targeting therapy and reported in breast cancer committees.
|
